Immunoglobulin Y

Compound Class	Immunoglobulin (antibody protein) — the avian functional equivalent of mammalian IgG. Not a small molecule; no CAS applies
Molecular Weight	~180 kDa (heavier than IgG, ~150 kDa)
Source	Gallus gallus domesticus — egg yolk of hens
Key Property	Specificity is everything. IgY raised against a given antigen binds that antigen. Non-specific IgY is a protein powder
Typical Standardisation	Total IgY by ELISA or SDS-PAGE; antigen-specific titre where applicable
Primary Applications	Oral passive immunisation against gut pathogens; oral care; research antibody production
Claim Strength (Overview)	Moderate for antigen-specific IgY against defined pathogens; Low for non-specific IgY as a general immune supplement
Buy from Herbuno	Egg IgY Powder - Gallus gallus domesticus →

Name origin: IgY is named for the yolk in which it is deposited — the "Y" distinguishing it from mammalian IgG. It is the avian functional analogue of IgG: hens transfer it from serum into the egg yolk to confer passive immunity on the developing chick, exactly as mammals transfer IgG across the placenta or in colostrum. It is a larger molecule than IgG (~180 vs ~150 kDa) and differs structurally in ways that matter commercially. Traditional use: None applies. Eggs are among the oldest human foods, but IgY as an isolated functional protein is a product of 20th-century immunology, and no traditional system identified it. It would be dishonest to construct an ethnobotanical narrative here. Research trajectory: IgY technology developed as a practical alternative to mammalian antibody production, offering real advantages: it is non-invasive (antibodies are harvested from eggs rather than by bleeding animals), economically favourable, high-yielding, and — usefully for immunoassay work — IgY does not activate mammalian complement and does not bind protein A or G, which reduces background interference. Its therapeutic development has centred on oral passive immunisation against gastrointestinal pathogens. Commercial source: Spray-dried egg yolk IgY from Gallus gallus domesticus.

---

Evidence for Immunoglobulin Y Applications

The governing fact about IgY, which determines whether a given product is worth anything at all, is antigen specificity. IgY from hyperimmunised hens has been explored for passive treatment of specific infections, and the concept has been applied to dental caries, periodontitis and gingivitis, gastritis and gastric ulcer, oral thrush, and infant rotavirus diarrhoea — in every case using IgY raised against a defined target (Xu 2011 Hum Vaccin Immunother). The mechanism is simple binding: a specific antibody binds a specific pathogen or virulence factor and neutralises it. A generic "egg IgY" with no defined antigen specificity is, functionally, an expensive egg protein powder. This distinction is the whole ballgame and is routinely obscured. Claim strength: Moderate (for specific IgY).

The passive-immunity mechanism is well demonstrated in defined models. Work with anti-K88 fimbriae IgY against enterotoxigenic Escherichia coli in weaned piglets found that specific IgY above 5 mg/mL significantly inhibited bacterial growth relative to non-specific yolk powder, and that pretreatment with 50 mg/mL significantly decreased adhesion to intestinal mucus (Li 2019). Note the internal control — specific IgY versus non-specific yolk powder. That comparison is precisely the one a buyer should insist upon, and it is the one that most commercial IgY positioning quietly avoids. Claim strength: Moderate.

Gastric and proteolytic stability is the principal technical obstacle, and it is a real one rather than a formality. IgY is a protein and is susceptible to denaturation at low gastric pH and to digestion by pepsin and pancreatic proteases; for oral passive immunisation to work, sufficient intact antibody must survive to reach the target site in the gut. This is why the field has invested heavily in delivery technology — chitosan-alginate microcapsules and other encapsulation systems have been developed and evaluated specifically to protect IgY through gastric transit. A formulator supplying unencapsulated IgY for a lower-gut target should expect substantial losses. Claim strength: High (established protein chemistry).

The strongest human-relevant clinical signal is in rotavirus diarrhoea, and it is worth being precise about its status. Randomised placebo-controlled work has evaluated immunoglobulin Y as an adjunct to standard supportive therapy for rotavirus-associated diarrhoea in paediatric patients, and animal-model work in neonatal gnotobiotic piglets has shown IgY antibodies protecting against human-rotavirus-induced diarrhoea. This is a well-defined, mechanistically coherent, pathogen-specific application — and it is a very long way from a general "immune support" supplement claim. Claim strength: Emerging to Moderate.

A dental application deserves note because it is commercially tractable and mechanistically clean: anti-glucosyltransferase IgY has been shown to suppress salivary mutans streptococci in healthy young adults, with supporting rat work on egg-derived antibodies to glucosyltransferases and dental caries. Glucosyltransferase is the enzyme Streptococcus mutans uses to build cariogenic biofilm, so neutralising it is a targeted intervention with a clear endpoint. Oral care is arguably the most defensible commercial direction for IgY outside veterinary and clinical passive immunisation. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries Egg IgY Powder from Gallus gallus domesticus. Buyers must understand that the value of any IgY material is a function of its antigen specificity: IgY raised against a defined target binds that target, while non-specific IgY has no demonstrated function beyond that of an egg protein. Herbuno will discuss antigen-specific requirements at enquiry.

Dosing for IgY cannot be given as a generic figure, because the meaningful variable is not milligrams of total protein but specific antibody titre against the target antigen, and the required titre depends entirely on the pathogen, the site, and the delivery system. The piglet work above used specific IgY at 5–50 mg/mL for growth inhibition and adhesion blockade respectively — concentrations at the site of action, not oral doses. Formulators should specify a titre requirement rather than a mass, and should account for expected gastric losses when calculating what to administer to achieve a given concentration in the target region of the gut.

Analytical verification should specify total IgY content (by ELISA or SDS-PAGE) and — the number that actually matters — the antigen-specific titre against the defined target, which a generic product will not have. Request the immunisation protocol and antigen identity for any specific-IgY material. Because IgY is a protein, activity is a function of conformational integrity: processing temperature, spray-drying conditions, and pH history all matter, and a mass-based assay can pass while the antibody is denatured and functionally dead. Ask for functional binding data, not just protein content. Salmonella and standard egg-product microbiological testing apply.

IgY is derived from hen egg yolk and is generally well tolerated; a practical advantage in immunoassay contexts is that IgY does not activate mammalian complement and does not bind protein A or G. The overriding safety consideration is straightforward and non-negotiable: this is an egg product, and egg is a major regulated allergen. IgY must carry clear egg-allergen declaration in every market, and is contraindicated in individuals with egg allergy — a population that includes a meaningful fraction of young children, who are also the target demographic for several of IgY’s best-supported applications. That tension should be addressed explicitly in product design rather than buried in a footnote. Formulators should also note that IgY’s therapeutic applications sit close to medicinal-claim territory in most regulatory regimes, and passive-immunisation claims will attract scrutiny.

---

Frequently Asked Questions — Immunoglobulin Y

Does generic IgY do anything?
Not much, and this is the point most IgY marketing avoids. IgY works by antibody-antigen binding — IgY raised against a defined target binds that target and neutralises it. A generic "egg IgY" with no defined antigen specificity is functionally an expensive egg protein powder. The piglet studies used specific IgY versus non-specific yolk powder as the control, and that is the comparison a buyer should insist on.

Does IgY survive the stomach?
Not well without help, and this is the principal technical obstacle. IgY is a protein, susceptible to denaturation at gastric pH and to pepsin and pancreatic proteases. The field has invested heavily in encapsulation — chitosan-alginate microcapsules and similar — precisely to protect it through gastric transit. Unencapsulated IgY aimed at a lower-gut target should expect substantial losses.

What are the best-supported IgY applications?
Pathogen-specific oral passive immunisation. Rotavirus diarrhoea has the strongest human-relevant signal, with randomised work as an adjunct to supportive therapy. Anti-glucosyltransferase IgY has suppressed salivary mutans streptococci in adults, making oral care arguably the most commercially tractable direction. None of this supports a general "immune support" claim.

What is the main safety consideration?
It is an egg product, and egg is a major regulated allergen. IgY requires clear egg-allergen declaration in every market and is contraindicated in egg allergy — a population that includes a meaningful fraction of young children, who are also the target demographic for several of IgY's best-supported applications. That tension needs addressing in product design, not a footnote.

Related compounds: Polysaccharides, Beta-Glucans, L-Glutathione, Inulin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery